NPPA writes to UT over 1,000% margin on medicines

CHANDIGARH: Drug price regulator National Pharmaceutical Pricing Authority (NPPA) replied to the UT health department after it came to fore that the MRPs of a few medicines not under its price control had exceeded 1,000% margin.

The letter from NPPA was in response to a complaint of increased MRPs of three cough syrups. The anomaly was detected by UT health secretary Yashpal Garg.
Prior to taking action against the manufacturers, NPPA found that they had not submitted Form V, which is required to compare the hike as price escalation of more than 10% annually is not permitted.

The NPPA has asked the Parwanoo-based manufacturers to explain why the form was not submitted by the end of the month.
The mandate of NPPA is to ensure that drug prices are compliant with the Drugs (Prices Control) Order, 2013.
“The formulations contained in MCAIN, RICAINE & SUFIT-O brands are non-scheduled formulations under DPCO, 2013 and prices for the same are not fixed by NPPA. For non-scheduled formulations, manufacturers are at liberty to fix initial prices,” mentioned the letter from NPPA deputy director

Saurabh Bansal to the UT health secretary.
It added, “The manufacturers/marketers mentioned in your letter have not submitted Form-V to NPPA, as required under DPCO, 2013. Changes in MRP since 2013 are required to examine compliance with Para 20 of DPCO, 2013. Accordingly, these manufacturers/ marketers have been directed to submit the requisite data separately.”

Related Posts

  • Pharma
  • July 26, 2024
  • 127 views
US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Maryland: The US Food and Drug Administration (FDA) has warned Brassica Pharma for numerous good manufacturing practice (GMP) violations, including multiple instances of employees falsifying sterility and environmental monitoring data and…

  • Pharma
  • July 26, 2024
  • 125 views
Indian National Charged With Selling Counterfeit Cancer Drugs

HOUSTON: A federal grand jury has returned an indictment charging an Indian national with selling and shipping tens of thousands of dollars in counterfeit oncology pharmaceuticals into the United States,…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Indian National Charged With Selling Counterfeit Cancer Drugs

Indian National Charged With Selling Counterfeit Cancer Drugs

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

BIS Sanctioned 82 Medical Device Projects To Develop Standards

BIS Sanctioned 82 Medical Device Projects To Develop Standards

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD